On 7 January 2026 the Medicines and Healthcare products Regulatory Agency (MHRA) approved Nirogacestat hydrobromide (Ogsiveo) for adults with progressing desmoid tumours, a non‑cancerous growth of connective tissue that can damage nearby organs. The drug works by inhibiting proteins that drive tumour growth, and studies show it can extend the time patients live without disease progression and reduce the need for surgery. Common side effects include diarrhoea, rash, nausea, fatigue, low phosphate levels, headache and mouth inflammation, while a serious risk is premature menopause in over 10 % of users. The medication must not be taken during pregnancy and contraception is mandatory; a patient card is provided. Side‑effect reports should be sent to the MHRA Yellow Card scheme. More details are available on the MHRA website.
© Crown copyright, 2024, GOV.UK.
Summary adapted from content licensed under the Open Government Licence v3.0.
For details, see https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/.
Original source: https://www.gov.uk/
https://www.gov.uk/government/news/nirogacestat-hydrobromide-approved-to-treat-desmoid-tumours
Made by AI. If you spot anything of concern write us at contact@cybach.com. We’ll promptly correct irregularities.